GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » EPS (Diluted)

TTNP (Titan Pharmaceuticals) EPS (Diluted) : $-5.21 (TTM As of Dec. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Titan Pharmaceuticals EPS (Diluted)?

Titan Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.85. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-5.21.

Titan Pharmaceuticals's EPS (Basic) for the three months ended in Dec. 2024 was $-0.85. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $-5.21.

Titan Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2024 was $-0.85. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $-5.21.

During the past 3 years, the average EPS without NRIGrowth Rate was 35.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 48.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Titan Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 267.50% per year. The lowest was -40.70% per year. And the median was 26.50% per year.


Titan Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Titan Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals EPS (Diluted) Chart

Titan Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -96.60 -18.00 -15.19 -7.41 -5.23

Titan Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.62 -1.24 -2.29 -0.83 -0.85

Competitive Comparison of Titan Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, Titan Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's PE Ratio falls into.


;
;

Titan Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Titan Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2024 is calculated as

Diluted EPS (A: Dec. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-4.706-0)/0.899
=-5.23

Titan Pharmaceuticals's Diluted EPS for the quarter that ended in Dec. 2024 is calculated as

Diluted EPS (Q: Dec. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.79-0)/0.914
=-0.86

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Titan Pharmaceuticals  (NAS:TTNP) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Titan Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Titan Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Executives
Seow Gim Shen 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
Sire Group Ltd. 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Matthew Charles Mcmurdo director 1047 SEWARD AVE., WESTFIELD NJ 07090
Peter Louis Chasey director 3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129
Eric Howard Greenberg director 710 CARLYLE ST, WOODMERE NY 11598
Avraham Ben-tzvi director 44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544
Katherine Beebe director, officer: President and COO 400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080
Choon Hau Choong 10 percent owner NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060
David E. Lazar director, 10 percent owner, officer: Chief Executive Officer VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000
Activist Investing Llc other: Member of 10% owner group 1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036
Joseph A Akers director 630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Marc Rubin director, officer: Executive Chairman C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Dane Hallberg officer: See Remarks 400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080